<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0909245885
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TYGACIL 50MG LYOP. POW. FOR I.V.INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIGECYCLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1285.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="WYETH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            WYETH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01AA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tygacil is an antibiotic of the glycylcycline group that works by stopping the growth of bacteria that cause infections.</p><p>&nbsp;</p><p>Your doctor has prescribed Tygacil because you or your child at least 18 years old has one of the following types of serious infections:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated infection in the abdomen</p><p>&nbsp;</p><p>Tygacil is only used when your doctor thinks other antibiotics are not suitable.</p><p>&nbsp;</p><p>Tygacil should be used only to treat infections that are proven or strongly suspected to be caused by susceptibly bacteria.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be administered Tygacil</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to tigecycline, or any of the other ingredients of this medicine (listed in section 6). If you are allergic to tetracycline class antibiotics (e.g., minocycline, doxycycline, etc.), you may be allergic to tigecycline.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>Talk</strong><strong> to your doctor or nurse before receiving Tygacil:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have poor or slow wound healing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from diarrhoea before you are given Tygacil. If you develop diarrhoea during or after your treatment, tell your doctor at once. Do not take any diarrhoea medicine without first checking with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or previously had any side effects due to antibiotics belonging to the tetracycline class (e.g., skin sensitization to sun light, staining on developing teeth, pancreas inflammation, and alteration of certain laboratory values aimed at measuring how well your blood clots).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have, or previously had liver problems. Depending on the condition of your liver, your doctor may reduce the dose to avoid potential side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have blockage of the bile ducts (cholestasis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant and in your second or third trimester.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from a bleeding disorder or are in treatment with anticoagulant drugs, as this medicine can interfere with blood coagulation.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>During treatment with Tigecycline:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor immediately if you develop symptoms of an allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor immediately if you develop severe abdominal pain, nausea, and vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These may be symptoms of acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In certain serious infections, your doctor may consider using Tygacil in combination with other antibiotics.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will monitor you closely for the development of any other bacterial infections. If you develop another bacterial infection, your doctor may prescribe a different antibiotic specific for the type of infection present.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although antibiotics including Tygacil fight certain bacteria, other bacteria and fungi may continue to grow. This is called overgrowth. Your doctor will monitor you closely for any potential infections and treat you if necessary.</p><p>&nbsp;</p><p>Children and Adolescents</p><p>Tygacil is not to be used in children less than 18 years of age due to the lack of data on safety and efficacy in this age group and because it may induce permanent dental defects such as staining on the developing teeth.</p><p>&nbsp;</p><p>Other medicines and Tigecycline</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Tygacil may prolong certain tests that measure how well your blood is clotting. It is important that you tell your doctor if you are taking medicines to avoid an excess of blood clotting<em>.</em> If this were the case, your doctor will monitor you closely.</p><p>&nbsp;</p><p>Tygacil may interfere with the contraceptive pill (birth control pill). Talk to your doctor about the need for an additional method of contraception while receiving Tygacil.</p><p>&nbsp;</p><p>Tygacil may increase the effect of medicines used to suppress the immune system (such as tacrolimus or cyclosporine). It is important that you tell your doctor if you are taking these medicines so you can be closely monitored.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>Tygacil may cause foetal harm. If you are pregnant or breast-feeding, think you may be pregnant<em>,</em> or are planning to have a baby, talk to your doctor for advice before receiving Tygacil,</p><p>As Tygacil may cause permanent discoloration of baby teeth and reversible inhibition of bone growth when taken during the second and third trimesters of pregnancy.</p><p>&nbsp;</p><p>It is not known if Tygacil passes into breast milk in humans. Ask your doctor for advice before breast-feeding your baby.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Tygacil may cause side effects such as dizziness. This may impair your ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tigecycline will be given to you by a doctor or a nurse.</p><p>&nbsp;</p><p>The recommended dose is 100 mg given initially, followed by 50 mg every 12 hours. This dose is given intravenously (directly into your blood stream) over a period of 30 to 60 minutes.</p><p>&nbsp;</p><p>The recommended dose in children aged 8 to 11 years is 1.2 mg/kg given every 12 hours intravenously to a maximum dose of 50 mg every 12 hours.</p><p>&nbsp;</p><p>The recommended dose in adolescents aged 12 to 17 years is 50 mg given every 12 hours.</p><p>&nbsp;</p><p>A course of treatment usually lasts for 5 to 14 days. Your doctor will decide how long you should be treated.</p><p>&nbsp;</p><p>Tigecycline should be preferably administered over a 60-minute length of infusion in pediatric patients</p><p><strong>&nbsp;</strong></p><p><strong>Dosage in Elderly</strong></p><p>No dosage adjustment is necessary in elderly patients.</p><p>&nbsp;</p><p><strong>Dosage in Renal impairment</strong></p><p>No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis.</p><p><strong>&nbsp;</strong></p><p>If you receive more Tygacil than you should</p><p>If you are concerned that you may have been given too much Tygacil, talk to your doctor or nurse immediately.</p><p>&nbsp;</p><p>If you miss a dose of Tygacil</p><p>If you are concerned that you may have missed a dose, talk to your doctor or nurse immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Pseudomembranous colitis may occur with most antibiotics including Tygacil. This consists of severe, persistent or bloody diarrhoea associated with abdominal pain or fever, which can be a sign of serious bowel inflammation, which may occur during or after your treatment.</p><p>&nbsp;</p><p>Very common side effects are (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, diarrhoea.</p><p>&nbsp;</p><p>Common side effects are (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abscess (collection of pus), infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory measurements of decreased ability to form blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vein irritations from the injection, including pain, inflammation, swelling and clotting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, dyspepsia (stomach ache and indigestion), anorexia (loss of appetite)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus (itching), rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Poor or slow wound healing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in amylase, which is an enzyme found in the salivary glands and pancreas, increased blood urea nitrogen (BUN).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sepsis (severe infection in the body and blood stream)/septic shock (serious medical condition which can lead to multiple organ failure and death as a result of sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reaction (pain, redness, inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low protein levels in the blood</p><p>&nbsp;</p><p>Uncommon side effects are (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellow coloration of the skin), inflammation of the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low platelet levels in the blood (which may lead to an increased bleeding tendency and bruising/haematoma)</p><p>&nbsp;</p><p>Not known side effects are (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis/anaphylactoid reactions (that may range from mild to severe, including a sudden, generalised allergic reaction that may lead to a life-threatening shock [e.g. difficulty in breathing, drop of blood pressure, fast pulse]).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, which may lead to severe blistering and peeling of the skin (Stevens-Johnson Syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low fibrinogen levels in the blood (a protein involved in blood clotting)</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children.</p><p>&nbsp;</p><p>Store below 25 &ordm;C.</p><p>&nbsp;</p><p>Once reconstituted, TYGACIL must be used immediately.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the vial label. &nbsp;The expiry date refers to the last day of that month.<br /><br />Shelf life: 24 months.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Tigecycline.</p><p>The other ingredients are Lactose Monohydrate, Hydrochloric Acid, Sodium Hydroxide, Water for injection and Nitrogen.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	10 Vials. Each single-dose vial contains 50 mg tigecycline as an orange lyophilized powder for reconstitution for intravenous infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />Pfizer Europe MA EEIG, Boulevard de la Plaine, Bruxelles, Belgium<br />&nbsp;<br />Manufactured, Packed And Released By<br />Wyeth Lederle S.R.L, Via Franco Gorgone, Catania, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2020 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تيجاسيل هو مضاد حيوي من مجموعة جليسيل سيكلين يعمل من خلال إيقاف نمو البكتيريا التي تسبب العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وصف طبيبك تيجاسيل لأنك أنت أو طفلك تبلغان من العمر ١٨ عامًا على الأقل ومصابان بأحد الأنواع التالية من حالات العدوى الخطيرة:</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المعقدة في الجلد والأنسجة الرخوة (النسيج أسفل الجلد)، باستثناء عدوى القدم السكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المعقدة في البطن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">يُستخدم تيجاسيل فقط عندما يرى طبيبك أن المضادات الحيوية الأخرى غير مناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام تيجاسيل فقط لعلاج العدوى التي ثبت أو يشتبه بقوة أنها نتجت عن بكتيريا حساسة له.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال تيجاسيل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه تيجيسيكلين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦). إذا كنت مصابًا بالحساسية تجاه المضادات الحيوية من فئة تتراسيكلين (مثل، مينوسيكلين، دوكسيسيكلين، إلخ.)، فقد تكون مصابًا بالحساسية تجاه تيجيسيكلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال تيجاسيل</strong></p><p dir="RTL"><strong>تحدث مع طبيبك أو الممرضة قبل تلقي تيجاسيل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان التئام الجروح لديك ضعيفًا أو بطيئًا.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>إذا كنت تعاني من الإسهال قبل أن يتم إعطاؤك تيجاسيل. إذا أصبت بالإسهال أثناء أو بعد علاجك، فأخبر طبيبك على الفور. لا تتناول أي دواء لعلاج الإسهال دون الرجوع إلى طبيبك أولًا.<em> </em></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو سبق أن أصبت بأي آثار جانبية بسبب المضادات الحيوية التي تنتمي لفئة تتراسيكلين (مثل حساسية الجلد تجاه ضوء الشمس، والبقع على الأسنان النامية، والتهاب البنكرياس، وتغير في قيم اختبارات معملية معينة تهدف إلى قياس مدى كفاءة تجلط الدم لديك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو سبق أن أصبت بمشكلات في الكبد. بناءً على حالة كبدك، قد يقلل طبيبك الجرعة لتجنب الآثار الجانبية المحتملة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بانسداد في قنوات الصفراء (ركود صفراوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا وكنتِ في الثلث الثاني أو الثالث من الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب يتعلق بالنزيف أو كنت تخضع للعلاج باستخدام عقاقير مضادة للتخثر، حيث يمكن أن يتداخل هذا الدواء مع تخثر الدم.</p><p dir="RTL">&nbsp;</p><p>أثناء العلاج باستخدام تيجيسيكلين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فورًا إذا أصبت بأعراض تفاعل حساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فورًا إذا أصبت بألم شديد في البطن، وغثيان، وقيء.</p><p dir="RTL">فقد تكون هذه أعراض التهاب البنكرياس الحاد (البنكرياس الملتهب الذي قد يؤدي إلى ألم شديد في البطن، وغثيان، وقيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض حالات العدوى الخطيرة، قد يفكر طبيبك في استخدام تيجاسيل بالتزامن مع مضادات حيوية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيراقبك طبيبك عن كثب تحسبًا للإصابة بأي حالات عدوى بكتيرية أخرى. إذا أصبت بعدوى بكتيرية أخرى، فقد يصف طبيبك مضادًا حيويًا مختلفًا مخصصًا لعلاج نوع العدوى الحالية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالرغم من أن المضادات الحيوية بما في ذلك تيجاسيل تقاوم بكتيريا معينة، إلا أن أنواعًا أخرى من البكتيريا والفطريات قد تستمر في النمو. ويُسمى هذا فرط النمو. سيراقبك طبيبك عن كثب تحسبًا لظهور أي حالات عدوى محتملة وسيعالجك إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">تيجاسيل غير مخصص للاستخدام مع الأطفال الذين يقل عمرهم عن ١٨ عامًا بسبب نقص البيانات الخاصة بالسلامة والفعالية في هذه الفئة العمرية ولأنه قد يؤدي إلى عيوب دائمة في الأسنان مثل البقع على الأسنان النامية.</p><p dir="RTL">&nbsp;</p><p>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يطيل تيجاسيل من زمن اختبارات معينة تقيس مدى كفاءة تجلط الدم لديك. من المهم أن تخبر طبيبك إذا كنت تتناول أدوية لتجنب زيادة معدل تجلط الدم. إذا كان الأمر كذلك، فسيراقبك طبيبك عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتعارض تيجاسيل مع حبوب منع الحمل. تحدثي مع طبيبكِ بشأن الحاجة إلى وسيلة إضافية لمنع الحمل أثناء تلقي تيجاسيل<em>.</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">قد يزيد تيجاسيل من تأثير الأدوية المستخدمة لكبت جهاز المناعة (مثل تاكروليمس أو سيكلوسبورين). من المهم أن تخبر طبيبك إذا كنت تتناول هذه الأدوية حتى تتم مراقبتك عن كثب.</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة</p><p dir="RTL">قد يسبب تيجاسيل ضررًا للجنين. إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للحمل، فتحدثي مع طبيبكِ لاستشارته قبل تلقي تيجاسيل، فقد يسبب تيجاسيل تغيرًا دائمًا في لون أسنان الطفل وتثبيطًا قابلًا للعكس في نمو العظام عند تناوله خلال الثلثين الثاني والثالث من الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس معروفًا ما إذا كان تيجاسيل يمر في لبن الثدي لدى البشر أم لا. قومي باستشارة طبيبكِ قبل أن ترضعي طفلكِ رضاعة طبيعية.<em> </em></p><p dir="RTL">&nbsp;</p><p>تأثير تيجاسيل على القيادة واستخدام الآلات</p><p dir="RTL">قد يسبب تيجاسيل آثارًا جانبية مثل الدوار. وقد يضعف ذلك من قدرتك على القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك تيجيسيكلين بواسطة طبيب أو ممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي ١٠٠ ملجم تُعطى في البداية، تليها جرعة قدرها ٥٠ ملجم كل ١٢ ساعة. تُعطى هذه الجرعة عن طريق الوريد (مباشرةً في مجرى دمك) على مدار فترة من ٣٠ إلى ٦٠ دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها للأطفال الذين تتراوح أعمارهم بين ٨ أعوام و١١ عامًا هي ١,٢ ملجم/كلجم تُعطى كل ١٢ ساعة عن طريق الوريد، بحد أقصى للجرعة ٥٠ ملجم كل ١٢ ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها للمراهقين الذين تتراوح أعمارهم بين ١٢ و١٧ عامًا هي ٥٠ ملجم تُعطى كل ١٢ ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تستمر دورة العلاج عادةً لمدة ٥ أيام إلى ١٤ يومًا. سيقرر طبيبك المدة التي ينبغي علاجك خلالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُفضل إعطاء تيجيسيكلين على مدار فترة مدتها ٦٠ دقيقة من التسريب في المرضى من الأطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة في المسنين</strong></p><p dir="RTL">لا يلزم تعديل الجرعة مع المرضى من المسنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة في حالة الخلل الكلوي</strong></p><p dir="RTL">لا يلزم تعديل الجرعة مع المرضى المصابين بخلل كلوي أو مع المرضى الذين يخضعون للديلزة الدموية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p>الجرعة الزائدة من تيجاسيل</p><p dir="RTL">إذا كنت قلقًا من احتمال أنك قد تلقيت جرعة أكبر مما ينبغي من تيجاسيل، فتحدث مع طبيبك أو الممرضة فورًا.</p><p dir="RTL">&nbsp;</p><p>نسيان تناول جرعة من تيجاسيل</p><p dir="RTL">إذا كنت قلقًا من احتمال أن تكون فاتتك إحدى الجرعات، فتحدث مع طبيبك أو الممرضة فورًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحدث التهاب القولون الغشائي الكاذب مع معظم المضادات الحيوية بما في ذلك تيجاسيل. يتكون هذا من إسهال شديد، أو مستمر، أو دموي مصحوب بألم البطن أو الحمى، وهو ما يمكن أن يكون علامة على الإصابة بالتهاب خطير في الأمعاء قد يحدث أثناء علاجك أو بعده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص) هي:<br />&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القيء، الإسهال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص) هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخراج (تجمع القيح)، حالات العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قياسات معملية تفيد بانخفاض القدرة على تكوين الجلطات الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج الوريد بسبب الحقن، بما في ذلك الشعور بألم، والالتهاب، والتورم، وتجلط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن، سوء الهضم (ألم في المعدة وعسر هضم)، القهم (فقدان الشهية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات الكبد، فرط بيليروبين الدم (زيادة الصباغ الصفراوي في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة، الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو بطء التئام الجروح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الأميلاز، وهو إنزيم يوجد في الغدد اللعابية والبنكرياس، زيادة نيتروجين يوريا الدم (BUN)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض سكر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتان (عدوى شديدة في الجسم ومجرى الدم)/الصدمة الإنتانية (حالة طبية خطيرة يمكن أن تؤدي إلى فشل أعضاء متعددة والوفاة نتيجةً للإنتان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع الحقن (الألم، الاحمرار، الالتهاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البروتين في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص) هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الحاد (التهاب في البنكرياس قد ينتج عنه ألم شديد في البطن، وغثيان، وقيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار لون الجلد)، التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفيحات الدموية في الدم (قد يؤدي إلى زيادة القابلية للنزيف، والتكدم/الورم الدموي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير المعروفة (لا يمكن تقدير معدل التكرار من البيانات المتاحة) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات التأقية/التاقانية (قد تتراوح من خفيفة إلى شديدة، بما في ذلك تفاعل حساسية معمم مفاجئ قد يؤدي إلى صدمة مهددة للحياة [مثل صعوبة في التنفس، انخفاض ضغط الدم، سرعة معدل النبض]).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الذي قد يؤدي إلى حالة شديدة من تبثر وتقشر الجلد (متلازمة ستيفنز-جونسون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الفبرينوجين في الدم (بروتين مشترك في عملية تخثر الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الأعراض الجانبية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>&nbsp;<p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: ١۹۹۹۹</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج الأخرى:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في درجة حرارة أقل من ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد تحضير تيجاسيل، يجب استخدامه فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القارورة.&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.<br /><br />مدة الصلاحية: ٢٤ شهرًا.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي تيجيسيكلين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي لاكتوز أحادي الهيدرات، وحمض الهيدروكلوريك، وهيدروكسيد الصوديوم، وماء للحقن، ونيتروجين.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>١٠ قارورات. كل قارورة مخصصة لجرعة فردية تحتوي على ٥٠ ملجم من تيجيسيكلين في صورة مسحوق مجفف بالتجميد برتقالي اللون مخصص لتحضير محلول للتسريب عن طريق الوريد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><div style="direction:ltr"><span style="text-align:unset">Marketing Authorisation Holder</span></div><div style="direction:ltr"><span style="text-align:unset">Pfizer Europe MA EEIG, Boulevard de la Plaine, Bruxelles, Belgium</span></div><div style="direction:ltr"><span style="text-align:unset">&nbsp;</span></div><div style="direction:ltr"><span style="text-align:unset">Manufactured, Packed And Released By</span></div><div style="direction:ltr"><span style="text-align:unset">Wyeth Lederle S.R.L, Via Franco Gorgone, Catania, Italy</span></div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/تشرين الثاني ٢٠٢٠
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TYGACIL
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each single-dose 5 mL glass vial and 10 mL glass vial contain 50 mg of tigecycline as an orange lyophilized powder for reconstitution. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DOSAGE FORMS AND STRENGTHS 

Each vial contain 50 mg of tigecycline as a lyophilized powder for reconstitution. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TYGACIL is a tetracycline-class antibacterial drug indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:</p><p>&nbsp;</p><p><strong>Complicated Skin and Skin Structure Infections </strong></p><p>TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of<strong> </strong>Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis.</p><p><strong>&nbsp;</strong></p><p><strong>Complicated Intra-abdominal Infections </strong></p><p>TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of &nbsp;Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and ‑resistant isolates), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros.</p><p>&nbsp;</p><p><strong>Limitations of Use</strong></p><p>&nbsp;</p><p>TYGACIL is not indicated for the treatment of diabetic foot infections. A clinical trial failed to demonstrate non-inferiority of TYGACIL for treatment of diabetic foot infections. TYGACIL is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia. In a comparative clinical trial, greater mortality and decreased efficacy were reported in TYGACIL-treated patients [see Special Warnings and Precautions for use (4.4)].</p><p><strong>&nbsp;</strong></p><p><strong>Usage</strong></p><p>&nbsp;</p><p>To reduce the development of drug-resistant bacteria and maintain the effective of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptibly bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibly patterns may contribute to the empiric selection of therapy.</p><p>&nbsp;</p><p>Appropriate specimens for bacteriology examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to tigecycline. TYGACIL may be initiated as empiric monotherapy before results of these tests are known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Recommended Adult Dosage </strong></p><p>&nbsp;</p><p>The recommended dosage regimen for TYGACIL is an initial dose of 100 mg, followed by 50&nbsp;mg every 12 hours. Intravenous infusions of TYGACIL should be administered over approximately 30 to 60 minutes every 12 hours.</p><p>&nbsp;</p><p>The recommended duration of treatment with TYGACIL for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days. The recommended duration of treatment with TYGACIL for community-acquired bacterial pneumonia is 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient&rsquo;s clinical and bacteriological progress.</p><p><strong>&nbsp;</strong></p><p><strong>Dosage in Patients with Hepatic Impairment </strong></p><p>&nbsp;</p><p>No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child&nbsp;Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by a reduced maintenance dose of 25&nbsp;mg every 12 hours. Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response [see Clinical Pharmacology (5.1) and Use in Specific Populations (4.6)].</p><p>&nbsp;</p><p><strong>Dosage in Pediatric Patients</strong></p><p>&nbsp;</p><p>The safety and efficacy of the proposed pediatric dosing regimens have not been evaluated due to the observed increase in mortality associated with TYGACIL in adult patients. Avoid use of TYGACIL in pediatric patients unless no alternative antibacterial drugs are available. Under these circumstances, the following doses are suggested:</p><p>&middot;&nbsp;&nbsp; Pediatric patients aged 8 to 11 years should receive 1.2 mg/kg of TYGACIL every 12 hours intravenously to a maximum dose of 50 mg of TYGACIL every 12 hours.</p><p>&middot;&nbsp;&nbsp; Pediatric patients aged 12 to 17 years should receive 50 mg of TYGACIL every 12 hours.</p><p>&nbsp;</p><p>The proposed pediatric doses of TYGACIL were chosen based on exposures observed in pharmacokinetic trials, which included small numbers of pediatric patients [see Use in Specific Populations (4.6) and Clinical Pharmacology (5.1)].</p><p>&nbsp;</p><p>There are no data to provide dosing recommendations in pediatric patients with hepatic impairment.</p><p>&nbsp;</p><p>Tigecycline should be preferably administered over a 60-minute length of infusion in pediatric patients</p><p>&nbsp;</p><p><strong>Dosage in Elderly</strong></p><p>&nbsp;</p><p>No dosage adjustment is necessary in elderly patients.</p><p>&nbsp;</p><p><strong>Dosage in Renal impairment</strong></p><p>&nbsp;</p><p>No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis.</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring of Blood Coagulation Parameters</strong></p><p>&nbsp;</p><p>Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL [see Special Warnings and Precautions for use (4.4)].</p><p><strong>&nbsp;</strong></p><p><strong>Preparation and Administration </strong></p><p>&nbsp;</p><p>Each vial of TYGACIL should be reconstituted with 5.3 mL of 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer&rsquo;s Injection, USP to achieve a concentration of 10 mg/mL of tigecycline. (Note: Each vial contains a 6% overage. Thus, 5 mL of reconstituted solution is equivalent to 50&nbsp;mg of the drug.) The vial should be gently swirled until the drug dissolves. Reconstituted solution must be transferred and further diluted for intravenous infusion. Withdraw 5&nbsp;mL of the reconstituted solution from the vial and add to a 100 mL intravenous bag for infusion (for a 100 mg dose, reconstitute two vials; for a 50 mg dose, reconstitute one vial). The maximum concentration in the intravenous bag should be 1&nbsp;mg/mL. <u>The reconstituted solution should be yellow to orange in color; if not, the solution should be discarded.</u> Parenteral drug products should be inspected visually for particulate matter and discoloration (e.g., green or black) prior to administration. Once reconstituted, TYGACIL may be stored at room temperature (not to exceed 30&ordm;C) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag). If the storage conditions exceed 30&ordm;C after reconstitution, tigecycline should be used immediately. Alternatively, TYGACIL mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2&deg; to 8&deg;C (36&deg; to 46&deg;F) for up to 48 hours following immediate transfer of the reconstituted solution into the intravenous bag.&nbsp;</p><p>&nbsp;</p><p>TYGACIL may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of TYGACIL with 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP or Lactated Ringer&rsquo;s Injection, USP. Injection should be made with an infusion solution compatible with tigecycline and with any other drug(s) administered via this common line.</p><p>&nbsp;</p><p><strong>Drug Compatibilities</strong></p><p>&nbsp;</p><p>Compatible intravenous solutions include 0.9% Sodium Chloride Injection, USP, 5%&nbsp;Dextrose Injection, USP, and Lactated Ringer&rsquo;s Injection, USP. When administered through a Y-site, TYGACIL is compatible with the following drugs or diluents when used with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer&rsquo;s, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Patients hypersensitive to tetracycline class antibiotics may be hypersensitive to TIGECYCLINE.
TYGACIL is contraindicated for use in patients who have known hypersensitivity to tigecycline. Reactions have included anaphylactic reactions [see Warnings and Precautions (4.4) and Adverse Reactions (4.8)]. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>All-Cause Mortality</strong></p><p>&nbsp;</p><p>An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in TYGACIL-treated patients versus comparator-treated patients. In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4.0% (150/3788) of patients receiving TYGACIL and 3.0% (110/3646) of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, the adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between TYGACIL and comparator-treated patients. An analysis of mortality in all trials conducted for approved indications (cSSSI, cIAI, and CABP), including post-market trials showed an adjusted mortality rate of 2.5% (66/2640) for tigecycline and 1.8% (48/2628) for comparator, respectively. The adjusted risk difference for mortality stratified by trial weight was 0.6% (95% CI 0.0, 1.2).</p><p>&nbsp;</p><p>The cause of this mortality difference has not been established. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. <strong>&nbsp;</strong>TYGACIL should be reserved for use in situations when alternative treatments are not suitable [see Boxed Warning, Indications and Usage (4.1), Warnings and Precautions (4.4) and Adverse Reactions (4.8)].</p><p>&nbsp;</p><p><strong>Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia</strong></p><p>&nbsp;</p><p>A trial of patients with hospital acquired, including ventilator-associated, pneumonia failed to demonstrate the efficacy of TYGACIL. In this trial, patients were randomized to receive TYGACIL (100 mg initially, then 50 mg every 12 hours) or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who received TYGACIL had lower cure rates (47.9% versus 70.1% for the clinically evaluable population).</p><p>&nbsp;</p><p>In this trial, greater mortality was seen in patients with ventilator-associated pneumonia who received TYGACIL (25/131 [19.1%] versus 15/122 [12.3%] in comparator-treated patients) [see Adverse Reactions (4.8)]. Particularly high mortality was seen among TYGACIL-treated patients with ventilator-associated pneumonia and bacteremia at baseline (9/18 [50.0%] versus 1/13 [7.7%] in comparator-treated patients).</p><p>&nbsp;</p><p><strong>Anaphylactic Reactions </strong></p><p>&nbsp;</p><p>Anaphylactic reactions have been reported with nearly all antibacterial agents, including TYGACIL, and may be life-threatening. TYGACIL is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs.</p><p>&nbsp;</p><p><strong>Hepatic Adverse Effects </strong></p><p>&nbsp;</p><p>Increases in total bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur after the drug has been discontinued.</p><p>&nbsp;</p><p><strong>Pancreatitis</strong></p><p>&nbsp;</p><p>Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk factors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis [see Adverse Reactions (4.8)].</p><p>&nbsp;</p><p><strong>Monitoring of Blood Coagulation Parameters </strong></p><p>&nbsp;</p><p>Hypofibrinogenemia has been reported in patients treated with TYGACIL <em>[see Undesirable effects (4.8)]</em>. Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL.&nbsp;</p><p>&nbsp;</p><p><strong>Tooth Discoloration and Enamel Hypoplasia</strong></p><p>&nbsp;</p><p>The use of TYGACIL during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth<strong> </strong>(yellow-gray-brown).<strong> </strong>&nbsp;This adverse reaction is more common during long-term use of tetracyclines, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Advise the patient of the potential risk to the fetus if TYGACIL is used during the second or third trimester of pregnancy [see Fertility, pregnancy and lactation (4.6)].</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Inhibition of Bone Growth</strong></p><p>&nbsp;</p><p>The use of TYGACIL during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the tetracycline was discontinued. Advise the patient of the potential risk to the fetus if TYGACIL is used during the second or third trimester of pregnancy [see Fertility, pregnancy and lactation (4.6)].</p><p>&nbsp;</p><p><strong>Clostridioides difficile Associated Diarrhea</strong></p><p>&nbsp;</p><p>Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.</p><p>&nbsp;</p><p>C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>&nbsp;</p><p>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.</p><p>&nbsp;</p><p><strong>Sepsis/Septic Shock in Patients With Intestinal Perforation</strong></p><p>&nbsp;</p><p>Monotherapy with tigecycline should be avoided in patients with complicated intra-abdominal infections (cIAI) secondary to clinically apparent intestinal perforation. In cIAI studies (n=1642), 6 patients treated with TYGACIL and 2 patients treated with imipenem/cilastatin presented with intestinal perforations and developed sepsis/septic shock. The 6 patients treated with TYGACIL had higher APACHE II scores (median = 13) versus the 2 patients treated with imipenem/cilastatin (APACHE II scores = 4 and 6). Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment cannot be established.</p><p>&nbsp;</p><p><strong>Tetracycline-Class Adverse Effects</strong></p><p>&nbsp;</p><p>TYGACIL is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects. Such effects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia).</p><p>&nbsp;</p><p><strong>Development of Drug-Resistant Bacteria</strong></p><p>&nbsp;</p><p>Prescribing TYGACIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p><p>&nbsp;</p><p><strong>Underlying diseases</strong></p><p>&nbsp;</p><p>Experience in the use of tigecycline for treatment of infections in patients with severe underlying diseases is limited.</p><p>&nbsp;</p><p>In clinical trials in cSSTI, the most common type of infection in tigecycline treated patients was cellulitis (58.6 %), followed by major abscesses (24.9 %). Patients with severe underlying disease, such as those that were immunocompromised, patients with decubitus ulcer infections, or patients that had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled. A limited number of patients were enrolled with co-morbid factors such as diabetes (25.8 %), peripheral vascular disease (10.4 %), intravenous substance abuse (4.0 %), and HIV-positive infection (1.2 %). Limited experience is also available in treating patients with concurrent bacteraemia (3.4 %). Therefore, caution is advised when treating such patients. The results in a large study in patients with diabetic foot infection showed that tigecycline was less effective than comparator, therefore, tigecycline is not recommended for use in these patients.</p><p>&nbsp;</p><p>In clinical trials in clAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9 .6 % ), perforation of intestine (9 .6 % ), intraabdominal abscess (8. 7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0 %). Of these patients, 77.8 % had surgically apparent peritonitis. There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores&gt; 15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %). Limited experience is also available in treating patients with concurrent bacteremia (5.6 %). Therefore, caution is advised when treating such patients.</p><p>&nbsp;</p><p>Consideration should be given to the use of combination antibacterial therapy whenever tigecycline is to be administered to severely ill patients with cIAI secondary to clinically apparent intestinal perforation or patients with incipient sepsis or septic shock.</p><p>&nbsp;</p><p>The effect of cholestasis in the pharmacokinetics of tigecycline has not been properly established. Biliary excretion accounts for approximately 50 % of the total tigecycline excretion. Therefore, patients presenting with cholestasis should be closely monitored.</p><p>&nbsp;</p><p>Prothrombin time or other suitable anticoagulation test should be used to monitor patients if tigecycline is administered with anticoagulants.</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibacterial agent.</p><p>&nbsp;</p><p>The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi. Patients should be carefully monitored during therapy.</p><p>Results of studies in rats with tigecycline have shown bone discoloration. Tigecycline may be associated with permanent tooth discoloration in humans if used during tooth development.</p><p><em>&nbsp;</em></p><p><strong>Pediatric population</strong></p><p>&nbsp;</p><p>Nausea and vomiting are very common adverse reactions in children and adolescents. Attention should be paid to possible dehydration.</p><p>Abdominal pain is commonly reported in children as it is in adults. Abdominal pain may be indicative of pancreatitis. If pancreatitis develops, treatment with tigecycline should be discontinued.</p><p>Liver function tests, coagulation parameters, hematology parameters, amylase and lipase should be monitored prior to treatment initiation with tigecycline and regularly while on treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Warfarin </strong></p><p>&nbsp;</p><p>Prothrombin time or other suitable anticoagulation test should be monitored if TYGACIL is administered with warfarin [see Clinical Pharmacology (5.1)].</p><p>&nbsp;</p><p><strong>Calcineurin Inhibitors</strong></p><p>&nbsp;</p><p>Concomitant use of TYGACIL and calcineurin inhibitors such as tacrolimus or cyclosporine may lead to an increase in serum trough concentrations of the calcineurin inhibitors. Therefore, serum concentrations of the calcineurin inhibitor should be monitored during treatment with TYGACIL to avoid drug toxicity.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Oral Contraceptives </strong></p><p>&nbsp;</p><p>Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy </strong></p><p>&nbsp;</p><p><u>Risk Summary</u></p><p>&nbsp;</p><p>TYGACIL, like other tetracycline class antibacterial drugs, may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [see Special warnings and Precautions (4.4), Data, and Fertility, pregnancy and lactation (4.6)]. There are no available data on the risk of major birth defects or miscarriage following the use of TYGACIL during pregnancy. Administration of intravenous tigecycline in pregnant rats and rabbits during the period of organogenesis was associated with reduction in fetal weights and an increased incidence of skeletal anomalies (delays in bone ossification) at exposures of 5 and 1 times the human exposure at the recommended clinical dose in rats and rabbits, respectively. Advise the patient of the potential risk to the fetus if TYGACIL is used during the second or third trimester.</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U. S. general population, the estimated background risk in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p><u>&nbsp;</u></p><p><u>Data</u></p><p><em>&nbsp;</em></p><p><em>Human Data </em></p><p>&nbsp;</p><p>The use of tetracycline-class antibacterial drugs, that includes TYGACIL, during tooth development (second and third trimester of pregnancy) may cause permanent discoloration of deciduous teeth. This adverse reaction is more common during long-term use of tetracyclines but has been observed following repeated short-term courses. TYGACIL may cause reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours.</p><p>&nbsp;</p><p>Animal Data</p><p>&nbsp;</p><p>In embryo-fetal development studies, tigecycline was administered during the period of organogenesis at doses up to 12&nbsp;mg/kg/day in rats and 4&nbsp;mg/kg in rabbits or 5 and 1 times the systemic exposure at the recommended clinical dose, respectively. In the rat study, decreased fetal weight and fetal skeletal variations (reduced ossification of the pubic, ischial, and supraoccipital bones and increased incidences of rudimentary 14<sup>th</sup> rib) were observed in the presence of maternal toxicity at 12&nbsp;mg/kg/day (5 times the recommended clinical dose based on systemic exposure). In rabbits, decreased fetal weights were observed in the presence of maternal toxicity at 4&nbsp;mg/kg (equivalent to the human exposure at the recommended clinical dose).</p><p>&nbsp;</p><p>In preclinical safety studies, <sup>14</sup>C-labeled tigecycline crossed the placenta and was found in fetal tissues.</p><p>&nbsp;</p><p><strong>Lactation </strong></p><p><u>&nbsp;</u></p><p><u>Risk Summary</u></p><p>&nbsp;</p><p>There are no data on the presence of tigecycline in human milk; however, tetracycline-class antibacterial drugs are present in breast milk. It is not known whether tigecycline has an effect on the breastfed infant or on milk production. Tigecycline has low oral bioavailability; therefore, infant exposure is expected to be low. Tigecycline is present in rat milk with little or no systemic exposure to tigecycline in nursing pups as a result of exposure via maternal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk.</p><p>&nbsp;</p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for TYGACIL and any potential adverse effects on the breastfed child from TYGACIL or from the underlying maternal condition (see Clinical Considerations).</p><p><u>&nbsp;</u></p><p><u>Clinical Considerations </u></p><p>&nbsp;</p><p>Because of the theoretical risk of dental discoloration and inhibition of bone growth, avoid breastfeeding if taking TYGACIL for longer than three weeks. A lactating woman may also consider interrupting breastfeeding and pumping and discarding breastmilk during administration of TYGACIL and for 9 days (approximately 5 half-lives) after the last dose in order to minimize drug exposure to a breastfed infant.</p><p>&nbsp;</p><p><strong>Pediatric Use </strong></p><p>&nbsp;</p><p>Use in patients under 18 years of age is not recommended. Safety and effectiveness in pediatric patients below the age of 18 years have not been established. Because of the increased mortality observed in TYGACIL-treated adult patients in clinical trials, pediatric trials of TYGACIL to evaluate the safety and efficacy of TYGACIL were not conducted.</p><p>&nbsp;</p><p>In situations where there are no other alternative antibacterial drugs, dosing has been proposed for pediatric patients 8 to 17 years of age based on data from pediatric pharmacokinetic studies [see Dosage and Administration (4.2) and Clinical Pharmacology (5.1)].</p><p>&nbsp;</p><p>Because of effects on tooth development, use in patients under 8 years of age is not recommended [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p><strong>Geriatric Use </strong></p><p>&nbsp;</p><p>Of the total number of subjects who received TYGACIL in Phase 3 clinical studies (n=2514), 664 were 65 and over, while 288 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity to adverse events of some older individuals cannot be ruled out.</p><p>&nbsp;</p><p>No significant difference in tigecycline exposure was observed between healthy elderly subjects and younger subjects following a single 100 mg dose of tigecycline [see Clinical Pharmacology (5.1)].</p><p>&nbsp;</p><p><strong>Hepatic Impairment </strong></p><p>&nbsp;</p><p>No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child&nbsp;Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of tigecycline should be 100 mg followed by a reduced maintenance dose of 25&nbsp;mg every 12 hours. Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response [see Clinical Pharmacology (5.1) and Dosage and Administration (4.2)].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tygacil may cause side effects such as dizziness. This may impair your ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adverse Reactions</strong></p><p><strong>&nbsp;</strong></p><p>The following serious adverse reactions are described elsewhere in the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All-Cause Mortality [see Boxed Warning and Warnings and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia [see Warnings and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis [Warning and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic Adverse Effects [Warnings and Precautions (4.4)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis [Warnings and Precautions (4.4)]</p><p><strong>&nbsp;</strong></p><p><strong>Clinical Trials Experience </strong></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>In clinical trials, 2514 patients were treated with TYGACIL. TYGACIL was discontinued due to adverse reactions in 7% of patients compared to 6% for all comparators. Table 1 shows the incidence of adverse reactions through test of cure reported in &ge;2% of patients in these trials.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p>Table 1. Incidence (%) of Adverse Reactions Through Test of Cure Reported in &ge;&nbsp;2% of Patients Treated in Clinical Studies</p></td></tr><tr><td style="vertical-align:bottom"><p>Body System<br />&nbsp; &nbsp;Adverse Reactions</p></td><td style="vertical-align:bottom"><p>TYGACIL<br />(N=2514)</p></td><td style="vertical-align:bottom"><p>Comparators<sup>a</sup><br />(N=2307)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Body as a Whole</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Abdominal pain</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Abscess</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Asthenia</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Headache</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Infection</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular System</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Phlebitis</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Digestive System</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Diarrhea</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Dyspepsia</p></td><td style="vertical-align:top"><p>2</p></td><td><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Nausea</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Vomiting</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Hemic and Lymphatic System</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Anemia</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic and Nutritional</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Alkaline Phosphatase<br />&nbsp;&nbsp;&nbsp;Increased</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Amylase Increased</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Bilirubinemia</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;BUN Increased</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Healing Abnormal</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Hyponatremia</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Hypoproteinemia</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;SGOT Increased<sup>b</sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;SGPT Increased<sup>b</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory System</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Pneumonia</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Dizziness</p></td><td style="vertical-align:top"><p>3</p></td><td><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Appendages</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Rash</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Vancomycin/Aztreonam, Imipenem/Cilastatin, Levofloxacin, Linezolid.</p><p><sup>b</sup> LFT abnormalities in TYGACIL-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which occurred more often on therapy.</p></td></tr></tbody></table><p>&nbsp;</p><p>In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4.0% (150/3788) of patients receiving TYGACIL and 3.0% (110/3646) of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, an adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between TYGACIL and comparator-treated patients (see Table 2). The cause of the imbalance has not been established. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="6"><p>Table 2. Patients with Outcome of Death by Infection Type</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>TYGACIL</p></td><td colspan="2" style="vertical-align:bottom"><p>Comparator</p></td><td style="vertical-align:bottom"><p>Risk Difference*</p></td></tr><tr><td style="vertical-align:bottom"><p>Infection Type</p></td><td style="vertical-align:bottom"><p>n/N</p></td><td style="vertical-align:bottom"><p>%</p></td><td style="vertical-align:bottom"><p>n/N</p></td><td style="vertical-align:bottom"><p>%</p></td><td style="vertical-align:bottom"><p>% (95% CI)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>cSSSI</p></td><td style="vertical-align:top"><p>12/834</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>6/813</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.7 (-0.3, 1.7)</p></td></tr><tr><td style="vertical-align:top"><p>cIAI</p></td><td style="vertical-align:top"><p>42/1382</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>31/1393</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.8 (-0.4, 2.0)</p></td></tr><tr><td style="vertical-align:top"><p>CAP</p></td><td style="vertical-align:top"><p>12/424</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>11/422</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>0.2 (-2.0, 2.4)</p></td></tr><tr><td style="vertical-align:top"><p>HAP</p></td><td style="vertical-align:top"><p>66/467</p></td><td style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>57/467</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>1.9 (-2.4, 6.3)</p></td></tr><tr><td style="vertical-align:top"><p>Non-VAP<sup>a</sup></p></td><td style="vertical-align:top"><p>41/336</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>42/345</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>0.0 (-4.9, 4.9)</p></td></tr><tr><td style="vertical-align:top"><p>VAP<sup>a</sup></p></td><td style="vertical-align:top"><p>25/131</p></td><td style="vertical-align:top"><p>19.1</p></td><td style="vertical-align:top"><p>15/122</p></td><td style="vertical-align:top"><p>12.3</p></td><td style="vertical-align:top"><p>6.8 (-2.1, 15.7)</p></td></tr><tr><td style="vertical-align:top"><p>RP</p></td><td style="vertical-align:top"><p>11/128</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>2/43</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>3.9 (-4.0, 11.9)</p></td></tr><tr><td style="vertical-align:top"><p>DFI</p></td><td style="vertical-align:top"><p>7/553</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>3/508</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.7 (-0.5, 1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Overall Adjusted</p></td><td style="vertical-align:top"><p>150/3788</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>110/3646</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>0.6 (0.1, 1.2)**</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>CAP = Community-acquired pneumonia; cIAI = Complicated intra-abdominal infections; cSSSI&nbsp;=&nbsp;Complicated skin and skin structure infections; HAP = Hospital-acquired pneumonia; VAP&nbsp;=&nbsp;Ventilator-associated pneumonia; RP = Resistant pathogens; DFI = Diabetic foot infections.</p><p>* The difference between the percentage of patients who died in TYGACIL and comparator treatment groups. The 95% CI for each infection type was calculated using the normal approximation method without continuity correction.</p><p>** Overall adjusted (random effects model by trial weight) risk difference estimate and 95% CI.</p><p><sup>a</sup> These are subgroups of the HAP population.</p><p>Note: The studies include 300, 305, 900 (cSSSI), 301, 306, 315, 316, 400 (cIAI), 308 and 313 (CAP), 311 (HAP), 307 [Resistant gram-positive pathogen study in patients with MRSA or Vancomycin-Resistant Enterococcus (VRE)], and 319 (DFI with and without osteomyelitis).</p></td></tr></tbody></table><p>&nbsp;</p><p>An analysis of mortality in all trials conducted for approved indications - cSSSI, cIAI, and CABP, including post-market trials (one in cSSSI and two in cIAI) - showed an adjusted mortality rate of 2.5% (66/2640) for tigecycline and 1.8% (48/2628) for comparator, respectively. The adjusted risk difference for mortality stratified by trial weight was 0.6% (95% CI 0.0, 1.2).&nbsp;</p><p>&nbsp;</p><p>In comparative clinical studies, infection-related serious adverse reactions were more frequently reported for subjects treated with TYGACIL (7%) versus comparators (6%). Serious adverse reactions of sepsis/septic shock were more frequently reported for subjects treated with TYGACIL (2%) versus comparators (1%). Due to baseline differences between treatment groups in this subset of patients, the relationship of this outcome to treatment cannot be established [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p>The most common adverse reactions were nausea and vomiting which generally occurred during the first 1 &ndash; 2 days of therapy. The majority of cases of nausea and vomiting associated with TYGACIL and comparators were either mild or moderate in severity. In patients treated with TYGACIL, nausea incidence was 26% (17% mild, 8% moderate, 1% severe) and vomiting incidence was 18% (11% mild, 6% moderate, 1% severe).</p><p>&nbsp;</p><p>In patients treated for complicated skin and skin structure infections (cSSSI), nausea incidence was 35% for TYGACIL and 9% for vancomycin/aztreonam; vomiting incidence was 20% for TYGACIL and 4% for vancomycin/aztreonam. In patients treated for complicated intra-abdominal infections (cIAI), nausea incidence was 25% for TYGACIL and 21% for imipenem/cilastatin; vomiting incidence was 20% for TYGACIL and 15% for imipenem/cilastatin. In patients treated for community-acquired bacterial pneumonia (CABP), nausea incidence was 24% for TYGACIL and 8% for levofloxacin; vomiting incidence was 16% for TYGACIL and 6% for levofloxacin.</p><p>&nbsp;</p><p>Discontinuation from TYGACIL was most frequently associated with nausea (1%) and vomiting (1%). For comparators, discontinuation was most frequently associated with nausea (&lt;1%).</p><p>&nbsp;</p><p>The following adverse reactions were reported (&lt;2%) in patients receiving TYGACIL in clinical studies:</p><p>&nbsp;</p><p>Body as a Whole: injection site inflammation, injection site pain, injection site reaction, septic shock, allergic&nbsp;reaction, chills, injection site edema, injection site phlebitis</p><p>&nbsp;</p><p>Cardiovascular System: thrombophlebitis</p><p>&nbsp;</p><p>Digestive System: anorexia, jaundice, abnormal stools</p><p>&nbsp;</p><p>Metabolic/Nutritional System: increased creatinine, hypocalcemia, hypoglycemia</p><p>&nbsp;</p><p>Special Senses: taste perversion</p><p>&nbsp;</p><p>Hemic and Lymphatic System: prolonged activated partial thromboplastin time (aPTT), prolonged prothrombin time (PT), eosinophilia, increased international normalized ratio (INR), thrombocytopenia</p><p>&nbsp;</p><p>Skin and Appendages: pruritus</p><p>&nbsp;</p><p>Urogenital System: vaginal moniliasis, vaginitis, leukorrhea</p><p>&nbsp;</p><p><strong>Post-Marketing Experience </strong></p><p>&nbsp;</p><p>Worldwide post-marketing adverse events have been identified during post-approval use of TYGACIL.</p><p>&nbsp;</p><p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylactic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatic cholestasis, and jaundice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions, including Stevens-Johnson Syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptomatic hypoglycemia in patients with and without diabetes mellitus</p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp;hypofibrinogenaemia [see special Warnings and Precautions for use (4.4)]</p><p>&nbsp;</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local requirements.<u> </u></p><p><br /><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>&nbsp;Call center : 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states: </strong></p><p>Please Contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdosage with tigecycline. Intravenous administration of TYGACIL at a single dose of 300 mg over 60 minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting. Tigecycline is not removed in significant quantities by hemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DESCRIPTION </strong></p><p>&nbsp;</p><p>TYGACIL (tigecycline) is a tetracycline class antibacterial for intravenous infusion. The chemical name of tigecycline is (4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. The empirical formula is C<sub>29</sub>H<sub>39</sub>N<sub>5</sub>O<sub>8</sub> and the molecular weight is 585.65.</p><p>&nbsp;</p><p>The following represents the chemical structure of tigecycline:</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="Chemical Structure"
 style='width:241.8pt;height:75pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="322" height="100" alt="Chemical Structure" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Figure 1: Structure of Tigecycline</p><p>&nbsp;</p><p>TYGACIL is an orange lyophilized powder or cake. Each TYGACIL single-dose 10 mL vial contains 50 mg tigecycline lyophilized powder for reconstitution for intravenous infusion and 100 mg of lactose monohydrate. The pH is adjusted with hydrochloric acid, and if necessary sodium hydroxide. The product does not contain preservatives.</p><p>&nbsp;</p><p><strong>CLINICAL PHARMACOLOGY </strong></p><p><strong>&nbsp;</strong></p><p><strong>Mechanism of Action </strong></p><p>&nbsp;</p><p>Tigecycline is a tetracycline class antibacterial [see Microbiology (5.1)].</p><p><strong>&nbsp;</strong></p><p><strong>Microbiology </strong></p><p><u>&nbsp;</u></p><p><u>Mechanism of Action</u></p><p>&nbsp;</p><p>Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic; however, TYGACIL has demonstrated bactericidal activity against isolates of S.&nbsp;pneumoniae and L. pneumophila.</p><p><u>&nbsp;</u></p><p><u>Resistance</u></p><p>&nbsp;</p><p>To date there has been no cross-resistance observed between tigecycline and other antibacterial drugs. Tigecycline is less affected by the two major tetracycline-resistance mechanisms, ribosomal protection and efflux. Additionally, tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target-site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerases). However, some ESBL-producing isolates may confer resistance to tigecycline via other resistance mechanisms. Tigecycline resistance in some bacteria (e.g. Acinetobacter calcoaceticus-Acinetobacter baumannii complex) is associated with multi-drug resistant (MDR) efflux pumps.</p><p><u>&nbsp;</u></p><p><u>Interaction with Other Antimicrobials</u></p><p>&nbsp;</p><p>In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterial drugs.</p><p><u>&nbsp;</u></p><p><u>Antimicrobial Activity</u></p><p>&nbsp;</p><p>Tigecycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (4.4)].</p><p>&nbsp;</p><p>Gram-positive bacteria</p><p>Enterococcus faecalis (vancomycin-susceptible isolates)</p><p>Staphylococcus aureus (methicillin-susceptible and -resistant isolates)</p><p>Streptococcus agalactiae</p><p>Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus)</p><p>Streptococcus pneumoniae (penicillin-susceptible isolates)</p><p>Streptococcus pyogenes</p><p>&nbsp;</p><p>Gram-negative bacteria</p><p>Citrobacter freundii</p><p>Enterobacter cloacae</p><p>Escherichia coli</p><p>Haemophilus influenzae</p><p>Klebsiella oxytoca</p><p>Klebsiella pneumoniae</p><p>Legionella pneumophila</p><p>&nbsp;</p><p>Anaerobic bacteria</p><p>Bacteroides fragilis</p><p>Bacteroides thetaiotaomicron</p><p>Bacteroides uniformis</p><p>Bacteroides vulgatus</p><p>Clostridium perfringens</p><p>Peptostreptococcus micros</p><p>&nbsp;</p><p>The following in vitro data are available, but their clinical significance is unknown.&nbsp; At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for tigecycline against isolates of similar genus or organism group.&nbsp; However, the efficacy of tigecycline in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</p><p>&nbsp;</p><p>Gram-positive bacteria</p><p>Enterococcus avium</p><p>Enterococcus casseliflavus</p><p>Enterococcus faecalis (vancomycin-resistant isolates)</p><p>Enterococcus faecium (vancomycin-susceptible and -resistant isolates)</p><p>Enterococcus gallinarum</p><p>Listeria monocytogenes</p><p>Staphylococcus epidermidis (methicillin-susceptible and -resistant isolates)</p><p>Staphylococcus haemolyticus</p><p>&nbsp;</p><p>Gram-negative bacteria</p><p>Acinetobacter baumannii*</p><p>Aeromonas hydrophila</p><p>Citrobacter koseri</p><p>Enterobacter aerogenes</p><p>Haemophilus influenzae (ampicillin-resistant)</p><p>Haemophilus parainfluenzae</p><p>Pasteurella multocida</p><p>Serratia marcescens</p><p>Stenotrophomonas maltophilia</p><p>&nbsp;</p><p>Anaerobic Bacteria</p><p>Bacteroides distasonis</p><p>Bacteroides ovatus</p><p>Peptostreptococcus spp.</p><p>Porphyromonas spp.</p><p>Prevotella spp.</p><p>&nbsp;</p><p>Other bacteria</p><p>Mycobacterium abscessus</p><p>Mycobacterium fortuitum</p><p>&nbsp;</p><p>*There have been reports of the development of tigecycline resistance in Acinetobacter infections seen during the course of standard treatment. Such resistance appears to be attributable to an MDR efflux pump mechanism. While monitoring for relapse of infection is important for all infected patients, more frequent monitoring in this case is suggested. If relapse is suspected, blood and other specimens should be obtained and cultured for the presence of bacteria. All bacterial isolates should be identified and tested for susceptibility to tigecycline and other appropriate antimicrobials.</p><p>&nbsp;</p><p><u>Susceptibility Testing</u></p><p>&nbsp;</p><p>For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see https://www.fda.gov/STIC.</p><p>&nbsp;</p><p><strong>Pharmacodynamics</strong></p><p><strong>&nbsp;</strong></p><p><strong>Cardiac Electrophysiology </strong></p><p>&nbsp;</p><p>No significant effect of a single intravenous dose of TYGACIL 50 mg or 200 mg on QTc interval was detected in a randomized, placebo- and active-controlled four-arm crossover thorough QTc study of 46 healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacokinetics </strong></p><p>The mean pharmacokinetic parameters of tigecycline after single and multiple intravenous doses based on pooled data from clinical pharmacology studies are summarized in Table 3. Intravenous infusions of tigecycline were administered over approximately 30 to 60 minutes.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3"><p>Table 3. Mean (CV%) Pharmacokinetic Parameters of Tigecycline</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Single Dose</p></td><td style="vertical-align:bottom"><p>Multiple Dose<sup>a</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>100 mg</p></td><td style="vertical-align:bottom"><p>50 mg every 12h</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>(N=224)</p></td><td style="vertical-align:bottom"><p>(N=103)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>C<sub>max</sub> (mcg/mL)<sup>b</sup></p></td><td><p>1.45 (22%)</p></td><td><p>0.87 (27%)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (mcg/mL)<sup>c</sup></p></td><td><p>0.90 (30%)</p></td><td><p>0.63 (15%)</p></td></tr><tr><td style="vertical-align:top"><p>AUC (mcg&middot;h/mL)</p></td><td><p>5.19 (36%)</p></td><td><p>- -</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-24h</sub> (mcg&middot;h/mL)</p></td><td><p>- -</p></td><td><p>4.70 (36%)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>min</sub> (mcg/mL)</p></td><td><p>- -</p></td><td><p>0.13 (59%)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub> (h)</p></td><td><p>27.1 (53%)</p></td><td><p>42.4 (83%)</p></td></tr><tr><td style="vertical-align:top"><p>CL (L/h)</p></td><td><p>21.8 (40%)</p></td><td><p>23.8 (33%)</p></td></tr><tr><td style="vertical-align:top"><p>CL<sub>r</sub> (mL/min)</p></td><td><p>38.0 (82%)</p></td><td><p>51.0 (58%)</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss</sub> (L)</p></td><td><p>568 (43%)</p></td><td><p>639 (48%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours</p><p><sup>b</sup> 30-minute infusion</p><p><sup>c</sup> 60-minute infusion</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL). The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.</p><p>&nbsp;</p><p>Following the administration of tigecycline 100 mg followed by 50 mg every 12 hours to 33&nbsp;healthy volunteers, the tigecycline AUC<sub>0-12h</sub> (134 mcg&middot;h/mL) in alveolar cells was approximately 78-fold higher than the AUC<sub>0-12h</sub> in the serum, and the AUC<sub>0-12h</sub> (2.28&nbsp;mcg&middot;h/mL) in epithelial lining fluid was approximately 32% higher than the AUC<sub>0-12h</sub> in serum. The AUC<sub>0-12h</sub> (1.61&nbsp;mcg&middot;h/mL) of tigecycline in skin blister fluid was approximately 26% lower than the AUC<sub>0-12h</sub> in the serum of 10 healthy subjects.</p><p>In a single-dose study, tigecycline 100 mg was administered to subjects prior to undergoing elective surgery or medical procedure for tissue extraction. Concentrations at 4 hours after tigecycline administration were higher in gallbladder (38-fold, n=6), lung (3.7-fold, n=5), and colon (2.3-fold, n=6), and lower in synovial fluid (0.58-fold, n=5), and bone (0.35-fold, n=6) relative to serum. The concentration of tigecycline in these tissues after multiple doses has not been studied.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><em>Metabolism</em></p><p>Tigecycline is not extensively metabolized. In vitro studies with tigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. In healthy male volunteers receiving <sup>14</sup>C-tigecycline, tigecycline was the primary <sup>14</sup>C-labeled material recovered in urine and feces, but a glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) were also present.</p><p>&nbsp;</p><p>Tigecycline is a substrate of P-glycoprotein (P-gp) based on an in vitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known.</p><p>&nbsp;</p><p>Excretion</p><p>The recovery of total radioactivity in feces and urine following administration of <sup>14</sup>C‑tigecycline indicates that 59% of the dose is eliminated by biliary/fecal excretion, and 33% is excreted in urine. Approximately 22% of the total dose is excreted as unchanged tigecycline in urine. Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline and its metabolites. Glucuronidation and renal excretion of unchanged tigecycline are secondary routes.</p><p><u>&nbsp;</u></p><p><u>Specific Populations</u></p><p><em>&nbsp;</em></p><p><em>Hepatic Impairment</em></p><p>&nbsp;</p><p>In a study comparing 10 patients with mild hepatic impairment (Child Pugh A), 10 patients with moderate hepatic impairment (Child Pugh B), and 5 patients with severe hepatic impairment (Child Pugh C) to 23 age and weight matched healthy control subjects, the single-dose pharmacokinetic disposition of tigecycline was not altered in patients with mild hepatic impairment. However, systemic clearance of tigecycline was reduced by 25% and the half-life of tigecycline was prolonged by 23% in patients with moderate hepatic impairment (Child Pugh B). Systemic clearance of tigecycline was reduced by 55%, and the half-life of tigecycline was prolonged by 43% in patients with severe hepatic impairment (Child Pugh C). Dosage adjustment is necessary in patients with severe hepatic impairment (Child Pugh C) [see Use in Specific Populations (4.6) and Dosage and Administration (4.2)].</p><p>&nbsp;</p><p><em>Renal Impairment</em></p><p>&nbsp;</p><p>A single dose study compared 6 subjects with severe renal impairment (creatinine clearance &lt;30&nbsp;mL/min), 4 end stage renal disease (ESRD) patients receiving tigecycline 2 hours before hemodialysis, 4 ESRD patients receiving tigecycline 1 hour after hemodialysis, and 6 healthy control subjects. The pharmacokinetic profile of tigecycline was not significantly altered in any of the renally impaired patient groups, nor was tigecycline removed by hemodialysis. No dosage adjustment of TYGACIL is necessary in patients with renal impairment or in patients undergoing hemodialysis.</p><p>&nbsp;</p><p><em>Geriatric Patients</em></p><p>&nbsp;</p><p>No significant differences in pharmacokinetics were observed between healthy elderly subjects (n=15, age 65-75; n=13, age &gt;75) and younger subjects (n=18) receiving a single 100-mg dose of TYGACIL. Therefore, no dosage adjustment is necessary based on age [see Use in Specific Populations (4.6)].</p><p>&nbsp;</p><p><em>Pediatric Patients</em></p><p>&nbsp;</p><p>A single-dose safety, tolerability, and pharmacokinetic study of tigecycline in pediatric patients aged 8-16 years who recently recovered from infections was conducted. The doses administered were 0.5, 1, or 2 mg/kg. The study showed that for children aged 12-16 years (n = 16) a dosage of 50 mg twice daily would likely result in exposures comparable to those observed in adults with the approved dosing regimen. Large variability observed in children aged 8 to 11 years of age (n = 8) required additional study to determine the appropriate dosage.</p><p>&nbsp;</p><p>A subsequent tigecycline dose-finding study was conducted in 8-11 year old patients with cIAI, cSSSI, or CABP. The doses of tigecycline studied were 0.75 mg/kg (n = 17), 1 mg/kg (n = 21), and 1.25 mg/kg (n=20). This study showed that for children aged 8-11 years, a 1.2 mg/kg dose would likely result in exposures comparable to those observed in adults resulting with the approved dosing regimen [see Dosage and Administration (4.2)].</p><p><em>&nbsp;</em></p><p><em>Gender</em></p><p>&nbsp;</p><p>In a pooled analysis of 38 women and 298 men participating in clinical pharmacology studies, there was no significant difference in the mean (&plusmn;SD) tigecycline clearance between women (20.7&plusmn;6.5 L/h) and men (22.8&plusmn;8.7 L/h). Therefore, no dosage adjustment is necessary based on gender.</p><p>&nbsp;</p><p><em>Race</em></p><p>&nbsp;</p><p>In a pooled analysis of 73 Asian subjects, 53 Black subjects, 15 Hispanic subjects, 190 White subjects, and 3 subjects classified as &ldquo;other&rdquo; participating in clinical pharmacology studies, there was no significant difference in the mean (&plusmn;SD) tigecycline clearance among the Asian subjects (28.8&plusmn;8.8 L/h), Black subjects (23.0&plusmn;7.8 L/h), Hispanic subjects (24.3&plusmn;6.5 L/h), White subjects (22.1&plusmn;8.9 L/h), and &ldquo;other&rdquo; subjects (25.0&plusmn;4.8 L/h). Therefore, no dosage adjustment is necessary based on race.</p><p><u>&nbsp;</u></p><p><u>Drug Interaction Studies</u></p><p>&nbsp;</p><p>Digoxin</p><p>&nbsp;</p><p>TYGACIL (100 mg followed by 50 mg every 12 hours) and digoxin (0.5&nbsp;mg followed by 0.25&nbsp;mg, orally, every 24 hours) were co-administered to healthy subjects in a drug interaction study. Tigecycline slightly decreased the C<sub>max</sub> of digoxin by 13%, but did not affect the AUC or clearance of digoxin. This small change in C<sub>max</sub> did not affect the steady-state pharmacodynamic effects of digoxin as measured by changes in ECG intervals. In addition, digoxin did not affect the pharmacokinetic profile of tigecycline. Therefore, no dosage adjustment of either drug is necessary when TYGACIL is administered with digoxin.</p><p>&nbsp;</p><p>Warfarin</p><p>&nbsp;</p><p>Concomitant administration of TYGACIL (100 mg followed by 50 mg every 12 hours) and warfarin (25&nbsp;mg single-dose) to healthy subjects resulted in a decrease in clearance of R‑warfarin and S‑warfarin by 40% and 23%, an increase in C<sub>max</sub> by 38% and 43% and an increase in AUC by 68% and 29%, respectively. Tigecycline did not significantly alter the effects of warfarin on INR. In addition, warfarin did not affect the pharmacokinetic profile of tigecycline. However, prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.</p><p>&nbsp;</p><p>In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, TYGACIL is not expected to alter the metabolism of drugs metabolized by these enzymes. In addition, because tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms.</p><p>&nbsp;</p><p>In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor. This in vitro information is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above.</p><p>&nbsp;</p><p>Tigecycline is a substrate of P-gp based on an in vitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known. Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>NONCLINICAL TOXICOLOGY </strong></p><p><strong>&nbsp;</strong></p><p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility </strong></p><p>Lifetime studies in animals have not been performed to evaluate the carcinogenic potential of tigecycline. No mutagenic or clastogenic potential was found in a battery of tests, including in&nbsp;vitro chromosome aberration assay in Chinese hamster ovary (CHO) cells, in vitro forward mutation assay in CHO cells (HGRPT locus), in vitro forward mutation assays in mouse lymphoma cells, and in vivo mouse micronucleus assay.</p><p>&nbsp;</p><p>Tigecycline did not affect mating or fertility in rats at exposures up to 5 times the human daily dose based on AUC (28 mcg&middot;hr/mL at 12 mg/kg/day). In female rats, there were no compound-related effects on ovaries or estrous cycles at exposures up to 5 times the human daily dose based on AUC.</p><p><strong>&nbsp;</strong></p><p><strong>Animal Toxicology and/or Pharmacology </strong></p><p>&nbsp;</p><p>In two week studies, decreased erythrocytes, reticulocytes, leukocytes, and platelets, in association with bone marrow hypocellularity, have been seen with tigecycline at exposures of 8&nbsp;times and 10 times the human daily dose based on AUC in rats and dogs, (AUC of approximately 50 and 60 mcg&middot;hr/mL at doses of 30 and 12 mg/kg/day) respectively. These alterations were shown to be reversible after two weeks of dosing.</p><p>&nbsp;</p><p><strong>CLINICAL STUDIES </strong></p><p><strong>&nbsp;</strong></p><p><strong>Complicated Skin and Skin Structure Infections </strong></p><p>&nbsp;</p><p>TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 1 and 2). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12&nbsp;hours) with vancomycin (1 g intravenous every 12&nbsp;hours)/aztreonam (2 g intravenous every 12 hours) for 5&nbsp;to&nbsp;14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (&ge;10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 4. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 5.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p>Table 4. Clinical Cure Rates from Two Studies in Complicated Skin and Skin Structure Infections after 5 to 14 Days of Therapy</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>TYGACIL<sup>a </sup><br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Vancomycin/Aztreonam<sup>b </sup><br />n/N (%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Study 1</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CE</p></td><td><p>165/199 (82.9)</p></td><td><p>163/198 (82.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c-mITT</p></td><td><p>209/277 (75.5)</p></td><td><p>200/260 (76.9)</p></td></tr><tr><td style="vertical-align:top"><p>Study 2</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CE</p></td><td><p>200/223 (89.7)</p></td><td><p>201/213 (94.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c-mITT</p></td><td><p>220/261 (84.3)</p></td><td><p>225/259 (86.9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours</p><p><sup>b</sup> Vancomycin (1 g every 12 hours)/Aztreonam (2 g every 12 hours)</p></td></tr></tbody></table><p>&amp; nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p>Table 5. Clinical Cure Rates By Infecting Pathogen in Microbiologically Evaluable Patients with Complicated Skin and Skin Structure Infections<sup>a</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Pathogen</p></td><td style="vertical-align:bottom"><p>TYGACIL<br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Vancomycin/Aztreonam<br />n/N (%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Escherichia coli</p></td><td><p>29/36 (80.6)</p></td><td><p>26/30 (86.7)</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacter cloacae</p></td><td><p>10/12 (83.3)</p></td><td><p>15/15 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Enterococcus faecalis (vancomycin-susceptible only)</p></td><td><p>15/21 (71.4)</p></td><td><p>19/24 (79.2)</p></td></tr><tr><td style="vertical-align:top"><p>Klebsiella pneumoniae</p></td><td><p>12/14 (85.7)</p></td><td><p>15/16 (93.8)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-susceptible Staphylococcus aureus (MSSA)</p></td><td><p>124/137 (90.5)</p></td><td><p>113/120 (94.2)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant Staphylococcus aureus (MRSA)</p></td><td><p>79/95 (83.2)</p></td><td><p>46/57 (80.7)</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus agalactiae</p></td><td><p>8/8 (100)</p></td><td><p>11/14 (78.6)</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus anginosus grp.<sup>b</sup></p></td><td><p>17/21 (81.0)</p></td><td><p>9/10 (90.0)</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pyogenes</p></td><td><p>31/32 (96.9)</p></td><td><p>24/27 (88.9)</p></td></tr><tr><td style="vertical-align:top"><p>Bacteroides fragilis</p></td><td><p>7/9 (77.8)</p></td><td><p>4/5 (80.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Two cSSSI pivotal studies and two Resistant Pathogen studies</p><p><sup>b</sup> Includes Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Complicated Intra-abdominal Infections </strong></p><p>&nbsp;</p><p>TYGACIL was evaluated in adults for the treatment of complicated intra-abdominal infections (cIAI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 1 and 2). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with imipenem/cilastatin (500 mg intravenous every 6 hours) for 5 to 14 days. Patients with complicated diagnoses including appendicitis, cholecystitis, diverticulitis, gastric/duodenal perforation, intra-abdominal abscess, perforation of intestine, and peritonitis were enrolled in the studies. The primary efficacy endpoint was the clinical response at the TOC visit for the co-primary populations of the microbiologically evaluable (ME) and the microbiologic modified intent-to-treat (m-mITT) patients. See Table 8. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p>Table 6. Clinical Cure Rates from Two Studies in Complicated Intra-abdominal Infections after 5 to 14 Days of Therapy</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>TYGACIL<sup>a </sup><br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Imipenem/Cilastatin<sup>b </sup><br />n/N (%)</p></td></tr></thead><tbody><tr><td><p>Study 1</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ME</p></td><td><p>199/247 (80.6)</p></td><td><p>210/255 (82.4)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m-mITT</p></td><td><p>227/309 (73.5)</p></td><td><p>244/312 (78.2)</p></td></tr><tr><td><p>Study 2</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ME</p></td><td><p>242/265 (91.3)</p></td><td><p>232/258 (89.9)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m-mITT</p></td><td><p>279/322 (86.6)</p></td><td><p>270/319 (84.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours</p><p><sup>b</sup> Imipenem/Cilastatin (500 mg every 6 hours)</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p>Table 7. Clinical Cure Rates By Infecting Pathogen in Microbiologically Evaluable Patients with Complicated Intra-abdominal Infections<sup>a</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Pathogen</p></td><td style="vertical-align:bottom"><p>TYGACIL<br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Imipenem/Cilastatin<br />n/N (%)</p></td></tr></thead><tbody><tr><td><p>Citrobacter freundii</p></td><td><p>12/16 (75.0)</p></td><td><p>3/4 (75.0)</p></td></tr><tr><td><p>Enterobacter cloacae</p></td><td><p>15/17 (88.2)</p></td><td><p>16/17 (94.1)</p></td></tr><tr><td><p>Escherichia coli</p></td><td><p>284/336 (84.5)</p></td><td><p>297/342 (86.8)</p></td></tr><tr><td><p>Klebsiella oxytoca</p></td><td><p>19/20 (95.0)</p></td><td><p>17/19 (89.5)</p></td></tr><tr><td><p>Klebsiella pneumoniae</p></td><td><p>42/47 (89.4)</p></td><td><p>46/53 (86.8)</p></td></tr><tr><td><p>Enterococcus faecalis</p></td><td><p>29/38 (76.3)</p></td><td><p>35/47 (74.5)</p></td></tr><tr><td><p>Methicillin-susceptible Staphylococcus aureus (MSSA)</p></td><td><p>26/28 (92.9)</p></td><td><p>22/24 (91.7)</p></td></tr><tr><td><p>Methicillin-resistant Staphylococcus&nbsp;aureus (MRSA)</p></td><td><p>16/18 (88.9)</p></td><td><p>1/3 (33.3)</p></td></tr><tr><td><p>Streptococcus anginosus grp.<sup>b</sup></p></td><td><p>101/119 (84.9)</p></td><td><p>60/79 (75.9)</p></td></tr><tr><td><p>Bacteroides fragilis</p></td><td><p>68/88 (77.3)</p></td><td><p>59/73 (80.8)</p></td></tr><tr><td><p>Bacteroides thetaiotaomicron</p></td><td><p>36/41 (87.8)</p></td><td><p>31/36 (86.1)</p></td></tr><tr><td><p>Bacteroides uniformis</p></td><td><p>12/17 (70.6)</p></td><td><p>14/16 (87.5)</p></td></tr><tr><td><p>Bacteroides vulgatus</p></td><td><p>14/16 (87.5)</p></td><td><p>4/6 (66.7)</p></td></tr><tr><td><p>Clostridium perfringens</p></td><td><p>18/19 (94.7)</p></td><td><p>20/22 (90.9)</p></td></tr><tr><td><p>Peptostreptococcus micros</p></td><td><p>13/17 (76.5)</p></td><td><p>8/11 (72.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Two cIAI pivotal studies and two Resistant Pathogen studies</p><p><sup>b</sup> Includes Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Community-Acquired Bacterial Pneumonia </strong></p><p>&nbsp;</p><p>TYGACIL was evaluated in adults for the treatment of community-acquired bacterial pneumonia (CABP) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 1 and 2). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12&nbsp;hours) with levofloxacin (500 mg intravenous every 12 or 24 hours). In Study 1, after at least 3 days of intravenous therapy, a switch to oral levofloxacin (500 mg daily) was permitted for both treatment arms. Total therapy was 7 to 14&nbsp;days. Patients with community-acquired bacterial pneumonia who required hospitalization and intravenous therapy were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co‑primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c‑mITT) patients. See Table 8. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 9.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="4"><p>Table 8. Clinical Cure Rates from Two Studies in Community-Acquired Bacterial Pneumonia after 7 to 14 Days of Total Therapy</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>TYGACIL<sup>a </sup><br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Levofloxacin<sup>b </sup><br />n/N (%)</p></td><td style="vertical-align:bottom"><p>95% CI<sup>c</sup></p></td></tr></thead><tbody><tr><td><p>Study 1<sup>d</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CE</p></td><td style="vertical-align:top"><p>125/138 (90.6)</p></td><td><p>136/156 (87.2)</p></td><td><p>(-4.4, 11.2)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c-mITT</p></td><td style="vertical-align:top"><p>149/191 (78)</p></td><td><p>158/203 (77.8)</p></td><td><p>(-8.5, 8.9)</p></td></tr><tr><td><p>Study 2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CE</p></td><td style="vertical-align:top"><p>128/144 (88.9)</p></td><td><p>116/136 (85.3)</p></td><td><p>(-5.0, 12.2)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c-mITT</p></td><td style="vertical-align:top"><p>170/203 (83.7)</p></td><td><p>163/200 (81.5)</p></td><td><p>(-5.6, 10.1)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours</p><p><sup>b</sup> Levofloxacin (500 mg intravenous every 12 or 24 hours)</p><p><sup>c</sup> 95% confidence interval for the treatment difference</p><p><sup>d</sup> After at least 3 days of intravenous therapy, a switch to oral levofloxacin (500 mg daily) was permitted for both treatment arms in Study 1.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p>Table 9. Clinical Cure Rates By Infecting Pathogen in Microbiologically Evaluable Patients with Community-Acquired Bacterial Pneumonia<sup>a</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Pathogen</p></td><td style="vertical-align:bottom"><p>TYGACIL<br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Levofloxacin<br />n/N<br />(%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Haemophilus influenzae</p></td><td><p>14/17 (82.4)</p></td><td><p>13/16 (81.3)</p></td></tr><tr><td style="vertical-align:top"><p>Legionella pneumophila</p></td><td><p>10/10 (100.0)</p></td><td><p>6/6 (100.0)</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pneumoniae (penicillin-susceptible<br />only)<sup>b</sup></p></td><td><p>44/46 (95.7)</p></td><td><p>39/44 (88.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Two CABP studies</p><p><sup>b</sup> Includes cases of concurrent bacteremia [cure rates of 20/22 (90.9%) versus 13/18 (72.2%) for TYGACIL and levofloxacin respectively]</p></td></tr></tbody></table><p>&nbsp;</p><p>To further evaluate the treatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical evidence. The higher-risk group included CABP patients from the two studies with any of the following factors:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age &ge;50 years</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PSI score &ge;3</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Streptococcus pneumoniae bacteremia</p><p>The results of this analysis are shown in Table 10. Age &ge;50 was the most common risk factor in the higher-risk group.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="4"><p>Table 10. Post-hoc Analysis of Clinical Cure Rates in Patients with Community-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>TYGACIL<br />n/N (%)</p></td><td style="vertical-align:bottom"><p>Levofloxacin<br />n/N<br />(%)</p></td><td style="vertical-align:bottom"><p>95% CI<sup>b</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Study 1<sup>c</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;CE</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;Higher risk</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;Yes</p></td><td><p>93/103 (90.3)</p></td><td><p>84/102 (82.4)</p></td><td><p>(-2.3, 18.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;No</p></td><td><p>32/35 (91.4)</p></td><td><p>52/54 (96.3)</p></td><td><p>(-20.8, 7.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;c-mITT</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;Higher risk</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;Yes</p></td><td><p>111/142 (78.2)</p></td><td><p>100/134 (74.6)</p></td><td><p>(-6.9, 14)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;No</p></td><td><p>38/49 (77.6)</p></td><td><p>58/69 (84.1)</p></td><td><p>(-22.8, 8.7)</p></td></tr><tr><td style="vertical-align:top"><p>Study 2</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;CE</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;Higher risk</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;Yes</p></td><td><p>95/107 (88.8)</p></td><td><p>68/85 (80)</p></td><td><p>(-2.2, 20.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;No</p></td><td><p>33/37 (89.2)</p></td><td><p>48/51 (94.1)</p></td><td><p>(-21.1, 8.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;c-mITT</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp;Higher risk</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;Yes</p></td><td><p>112/134 (83.6)</p></td><td><p>93/120 (77.5)</p></td><td><p>(-4.2, 16.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;No</p></td><td><p>58/69 (84.1)</p></td><td><p>70/80 (87.5)</p></td><td><p>(-16.2, 8.8)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> Patients at higher risk of death include patients with any one of the following: &ge;50 year of age; PSI score &ge;3; or bacteremia due to Streptococcus pneumoniae</p><p><sup>b</sup> 95% confidence interval for the treatment difference</p><p><sup>c</sup> After at least 3 days of intravenous therapy, a switch to oral levofloxacin (500 mg daily) was permitted for both treatment arms in Study 1.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>PATIENT COUNSELING INFORMATION</strong></p><p><strong>&nbsp;</strong></p><p><u>Tooth Discoloration and Inhibition of Bone Growth</u></p><p><u>&nbsp;</u></p><p>Advise pregnant women that TYGACIL may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p><u>Lactation </u></p><p>&nbsp;</p><p>Advise a woman not to breastfeed for longer than 3 weeks while taking TYGACIL because of the lack of data on effects due to prolonged breastfeeding, and the theoretical risk of dental discoloration and inhibition of bone growth. Women may also consider reducing infant exposure through pumping and discarding breastmilk during and for 9 days after the last dose of tigecycline [see Warnings and Precautions (4.4)].</p><p><em>&nbsp;</em></p><p><u>Diarrhea</u></p><p><strong>&nbsp;</strong></p><p>Advise patients, their families, or caregivers that diarrhea is a common problem caused by antibacterial drugs, including TYGACIL. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, advise patients to contact his or her healthcare provider [see Warnings and Precautions (4.4)].</p><p>&nbsp;</p><p><u>Development of Resistance </u></p><p>&nbsp;</p><p>Patients should be counseled that antibacterial drugs including TYGACIL should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When TYGACIL is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by TYGACIL or other antibacterial drugs in the future.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate, Hydrochloric Acid, Sodium Hydroxide, Water for injection, and Nitrogen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following drugs should not be administered simultaneously through the same Y-site as TYGACIL: amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole and omeprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 24 months.

Do not use Tygacil after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 &ordm;C.</p><p>&nbsp;</p><p>Once reconstituted, TYGACIL must be used immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A pack of 10 vials containing Powder for solution for infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer Europe MA EEIG, Boulevard de la Plaine, Bruxelles, Belgium
 
Manufactured, Packed And Released By
Wyeth Lederle S.R.L, Via Franco Gorgone, Catania, Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>